"versionIdentifier","id","instanceType","uuid:ID","rationale"
"2","StudyVersion_1","StudyVersion","44dccf6f-8395-4134-b41f-1e3e2b175fed","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
